Cannabidiol as a treatment in patients with movement disorder

Phase 1

• Conditions: Spinocerebellar Ataxia; C10.228.140.252.190

• Registration Number: RBR-36x4c4d
• Lead Sponsor: niversidade Federal do Paraná

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-11
• Last Update Posted: 26 July 2023
• Study Completion: 2023-08-07

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients from the Movement Disorders Outpatient Clinic of the Neurology Service of the Hospital de Clínicas - UFPR (HC - UFPR) over 18 years old who already had the genetic diagnosis of spinocerebellar ataxia type 10 (SCA10); patients who agreed and signed the Informed Consent Form.

Exclusion Criteria

Patients who did not agree with the Informed Consent Form; patients who did not have a genetic diagnosis of SCA10; demented patients; and patients who did not use the intervention correctly.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected to find improvement in the clinical evaluation of patients through observation and verification of the decrease in the score of the SARA scale (Scale for the Assessment and Rating of Ataxia) proven by ANOVA statistical analysis of repeated measures comparing the mean score of patients on the SARA scale on study day 0 (before intervention use) and on study day 30 (after one month of intervention use).

Secondary Outcome Measures

Name	Time	Method
It is expected to observe the safety and tolerability of the intervention through the observation and report of its adverse effects cited by the patients themselves.